-
2022-501901-10-00
6
2023-02-06
Chronic Hepatitis D Infection
-
2022-501744-15-00
5
2023-01-23
Obesity, Overweight
-
2024-510947-71-00
5
2022-11-21
Chronic Myeloid Leukemia
-
2023-505772-30-00
5
2022-11-09
Melanoma
-
2023-508265-33-00
5
2022-10-13
Vasomotor symptoms caused by adjuvant endocrine therapy in women with,
-
2023-509429-37-00
5
2022-10-03
Advanced or Metastatic Non-Small Cell Lung Cancer
-
2023-504195-14-00
5
2022-08-31
PD-L1-negative metastatic triple-negative breast cancer or PD-L1-posit
-
2024-513423-16-00
6
2022-08-25
Asthma
-
2023-509657-31-00
5
2022-08-24
Paroxysmal nocturnal haemoglobinuria (PNH)
-
2023-507933-12-00
5
2022-08-18
Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC)
-
2023-509943-28-00
5
2022-05-18
Stage IA2-IA3 non-small cell lung carcinoma, with EGFR mutation type (
-
2023-503517-30-00
5
2022-04-01
Extensive-stage small-cell lung cancer
-
2023-503640-14-00
5
2022-02-17
Newly diagnosed Philadelphia-negative B-cell precursor Acute Lymphobla
-
2023-506867-33-01
4
2022-01-25
Chronic Hepatitis B
-
2024-511599-33-00
5
2021-12-22
Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
-
2023-506241-30-00
5
2021-11-30
Advanced Colorectal Cancer with KRAS G12C Mutation
-
2023-509133-39-00
5
2021-11-29
Hormone receptor positive, HER2-negative advanced breast cancer
-
2024-510735-21-00
5
2021-11-26
Atherosclerotic cardiovascular disease (ASCVD)
-
2023-510319-20-00
5
2021-10-21
Gastroesophageal Adenocarcinoma (GEA)
-
2023-506256-25-00
5
2021-10-20
Active Psoriatic Arthritis
-
2023-506926-35-00
5
2021-09-24
Atherosclerotic cardiovascular disease, chronic kidney disease and sys
-
2023-507494-18-00
5
2021-09-24
Non-small cell lung cancer with ROS proto-oncogene 1, receptor tyrosin
-
2023-507963-20-00
5
2021-08-19
Metastatic Gastric Adenocarcinoma
-
2023-506752-24-00
5
2021-08-05
Locally recurrent inoperable or metastatic HR+/HER2- breast cancer, wh